Search Results 61-70 of 18034 for B cell lymphomas
The current diagnostic tools in a pathologist's arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one ...
The therapy, called axicabtagene ciloleucel (Yescarta), is approved to treat subtypes of lymphoma, including diffuse large B-cell lymphoma, primary mediastinal ...
Clinical Trials · Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma · More about research at Mayo ...
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
... B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL). Print details. Share; Facebook ...
... B-cell lymphomas and leukemias into remission. However, leukemia and lymphoma tumors can change over time and become resistant to therapies, resulting in a ...
Patients with large B-cell lymphoma who do not respond to an anthracycline-based front-line chemoimmunotherapy or who show evidence of relapse within 12 months ...
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer ...
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia ...
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma · Overview · Participation eligibility · Participating Mayo Clinic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The deadline to have twice the impact to advance healthcare research is May 15.